DiNAMIQS

www.dinamiqs.com

DiNAMIQS is a Contract Development and Manufacturing Organization (CDMO) revolutionizing gene therapy manufacturing and analytics. Based in Central Europe’s biotechnology hub Bio-Technopark Schlieren-Zürich, our state-of-the-art facility provides a comprehensive range of viral vector process development, manufacturing and analytical solutions to support and optimize the most promising gene therapy projects. With our innovative customized business interaction solutions, DiNAMIQS accelerates time to the clinic for its partners while reducing cost and risk. Our facility offers potent genetic medicine delivery vectors including high quality recombinant adeno-associated viral (AAV) vector manufacturing suitable for both in vitro and in vivo R&D applications up to 50L scale. Our highly skilled team has demonstrated success in biomanufacturing processes with more than 20 years’ experience in the field. DiNAMIQS is currently building a GMP-compliant facility that can produce viral vectors at 500L scale. Our team is led by Dr. Eduard Ayuso, one of the world’s leading experts in viral vector manufacturing and quality control. We serve clients globally from Bio-Technopark Schlieren-Zürich, the leading center for biotechnology companies in Central Europe, and home to our 1200 sqm state-of-the-art facility.

Read more

Reach decision makers at DiNAMIQS

Lusha Magic

Free credit every month!

DiNAMIQS is a Contract Development and Manufacturing Organization (CDMO) revolutionizing gene therapy manufacturing and analytics. Based in Central Europe’s biotechnology hub Bio-Technopark Schlieren-Zürich, our state-of-the-art facility provides a comprehensive range of viral vector process development, manufacturing and analytical solutions to support and optimize the most promising gene therapy projects. With our innovative customized business interaction solutions, DiNAMIQS accelerates time to the clinic for its partners while reducing cost and risk. Our facility offers potent genetic medicine delivery vectors including high quality recombinant adeno-associated viral (AAV) vector manufacturing suitable for both in vitro and in vivo R&D applications up to 50L scale. Our highly skilled team has demonstrated success in biomanufacturing processes with more than 20 years’ experience in the field. DiNAMIQS is currently building a GMP-compliant facility that can produce viral vectors at 500L scale. Our team is led by Dr. Eduard Ayuso, one of the world’s leading experts in viral vector manufacturing and quality control. We serve clients globally from Bio-Technopark Schlieren-Zürich, the leading center for biotechnology companies in Central Europe, and home to our 1200 sqm state-of-the-art facility.

Read more
icon

Country

icon

Employees

1-10

icon

Founded

2022

icon

Estimated Revenue

$1,000,000 to $5,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Head of Analytical Development

    Email ****** @****.com
    Phone (***) ****-****
  • Head of Business Development

    Email ****** @****.com
    Phone (***) ****-****
  • Head of Manufacturing - Preclinical Gene Therapy

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at DiNAMIQS

Free credits every month!

My account

Sign up now to uncover all the contact details